SG11201901444PA - Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods - Google Patents
Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methodsInfo
- Publication number
- SG11201901444PA SG11201901444PA SG11201901444PA SG11201901444PA SG11201901444PA SG 11201901444P A SG11201901444P A SG 11201901444PA SG 11201901444P A SG11201901444P A SG 11201901444PA SG 11201901444P A SG11201901444P A SG 11201901444PA SG 11201901444P A SG11201901444P A SG 11201901444PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- seattle
- kits
- avenue
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000004475 Arginine Substances 0.000 abstract 3
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 3
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) W I PO I iiiiono 1E1 oio llmonoloolo Elio° !moo im iflo °El (10) International Publication Number WO 2018/045054 Al PCT Av erag e Loa d ( lbf) 6 5 4 3 2 1 O 00 0 (51) International Patent Classification: A61K 9/08 (2006.01) A61K 47/00 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2017/049415 (22) International Filing Date: 30 August 2017 (30.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/382,156 31 August 2016 (31.08.2016) US (71) Applicant: OMEROS CORPORATION [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US). (72) Inventors; and (71) Applicants: DEMOPULOS, Gregory, A. [US/US]; 4845 Forest Avenue Se, Mercer Island, WA 98040 (US). FER- GUSON, Kenneth, M. [US/US]; 2125 First Avenue #2902, Seattle, WA 98121 (US). LAMBERT, William, Joseph [US/US]; 88 Virginia St. #23, Seattle, WA 98101 (US). WHITAKER, John, Steven [US/US]; 1510 40th Avenue, Seattle, WA 98122 (US). (74) Agent: QUINTON, Tineka; Omeros Corporation, 201 El- liott Avenue West, Seattle, WA 98119 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS Syringeability: Average Load 1 1 1 1 1 27 GA I 25 GA I 25 GA (Thin-Wall) 185 mg/mL 20 mM Citrate, 200 mM Arginine 0.01% PS-80, pH 5.8 27 GA I 25 GA I 25 GA (Thin-Wall) 185 mg/mL 20 mM Histidine, 200 mM Arginine 0.01% PS-80, pH 5.9 27 GA I 25 GA I 25 GA (Thin-Wall) 185 mg/mL 20 niM Citrate, 200 mM Arginine pH 5.8 FIG. 7A (57) : The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 C dependent complement activation. [Continued on next page] WO 2018/045054 Al MIDEDIMOMOIDEIREEMOMIVINIMEHIMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662382156P | 2016-08-31 | 2016-08-31 | |
PCT/US2017/049415 WO2018045054A1 (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901444PA true SG11201901444PA (en) | 2019-03-28 |
Family
ID=61301617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100697PA SG10202100697PA (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
SG11201901444PA SG11201901444PA (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100697PA SG10202100697PA (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Country Status (29)
Country | Link |
---|---|
US (2) | US11628217B2 (en) |
EP (1) | EP3506886B1 (en) |
JP (2) | JP6864747B2 (en) |
KR (2) | KR20190043161A (en) |
CN (3) | CN109890367B (en) |
AR (1) | AR109494A1 (en) |
AU (2) | AU2017321605B2 (en) |
BR (1) | BR112019003479A2 (en) |
CA (1) | CA3035252C (en) |
CL (1) | CL2019000508A1 (en) |
CO (1) | CO2019002239A2 (en) |
CR (1) | CR20190150A (en) |
CU (1) | CU20190015A7 (en) |
EA (1) | EA201990598A1 (en) |
EC (1) | ECSP19021312A (en) |
GE (1) | GEP20217252B (en) |
IL (1) | IL265071B2 (en) |
JO (1) | JOP20170170B1 (en) |
MA (1) | MA46109A (en) |
MX (2) | MX2019002338A (en) |
MY (1) | MY189411A (en) |
PE (1) | PE20190469A1 (en) |
PH (1) | PH12019500365A1 (en) |
SG (2) | SG10202100697PA (en) |
TW (2) | TWI719245B (en) |
UA (1) | UA122733C2 (en) |
UY (1) | UY37391A (en) |
WO (1) | WO2018045054A1 (en) |
ZA (1) | ZA201901891B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL294411A (en) * | 2016-01-05 | 2022-08-01 | Omeros Corp | Masp-2 inhibitors for use in inhibiting fibrosis |
JOP20170170B1 (en) * | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
JOP20190068A1 (en) * | 2016-10-13 | 2019-04-01 | Omeros Corp | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
BR112020003632A2 (en) * | 2017-08-25 | 2020-10-27 | Omeros Corporation | method of treating an individual who suffers or is at risk of developing ahus |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
US20220273796A1 (en) * | 2019-07-19 | 2022-09-01 | Ichnos Sciences SA | Lyophilized antibody formulation |
CA3159159A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
US20210179612A1 (en) | 2019-12-04 | 2021-06-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
IL300245A (en) * | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
AU2021365008A1 (en) * | 2020-10-22 | 2023-06-08 | Allakos Inc. | Anti-siglec-8 antibody formulations |
KR20240017071A (en) * | 2021-06-08 | 2024-02-06 | 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 | Anti-MASP-2 antibodies and uses thereof |
WO2024118840A1 (en) | 2022-11-30 | 2024-06-06 | Omeros Corporation | Fused pyrimidines as masp-2 inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP1962907A2 (en) | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
MX344322B (en) | 2009-10-16 | 2016-12-13 | Omeros Corp | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation. |
NZ746139A (en) | 2011-04-08 | 2023-11-24 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
KR102014512B1 (en) | 2011-05-02 | 2019-08-26 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | FORMULATION FOR ANTI-α4β7 ANTIBODY |
KR101641057B1 (en) * | 2011-05-04 | 2016-07-20 | 오메로스 코포레이션 | Compositions for inhibiting masp-2 dependent complement activation |
IN2015KN00015A (en) | 2012-06-18 | 2015-07-31 | Omeros Corp | |
WO2014141149A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
RU2020111211A (en) * | 2013-10-17 | 2021-11-08 | Омерос Корпорейшн | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT ACTIVATION OF COMPLEMENT |
BR112017003419A2 (en) * | 2014-09-03 | 2017-11-28 | Medimmune Ltd | stable anti-il-4r-alpha antibody formulation |
EP3240571A4 (en) | 2014-12-31 | 2018-06-13 | NovelMed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
WO2017083371A1 (en) | 2015-11-09 | 2017-05-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
IL294411A (en) | 2016-01-05 | 2022-08-01 | Omeros Corp | Masp-2 inhibitors for use in inhibiting fibrosis |
AU2017240129B2 (en) | 2016-03-31 | 2020-04-02 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
JOP20170170B1 (en) * | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
-
2017
- 2017-08-28 JO JOP/2017/0170A patent/JOP20170170B1/en active
- 2017-08-29 TW TW106129287A patent/TWI719245B/en active
- 2017-08-29 TW TW108111015A patent/TWI730310B/en active
- 2017-08-30 CN CN201780051640.7A patent/CN109890367B/en active Active
- 2017-08-30 KR KR1020197008678A patent/KR20190043161A/en not_active IP Right Cessation
- 2017-08-30 MA MA046109A patent/MA46109A/en unknown
- 2017-08-30 CR CR20190150A patent/CR20190150A/en unknown
- 2017-08-30 WO PCT/US2017/049415 patent/WO2018045054A1/en active Application Filing
- 2017-08-30 CA CA3035252A patent/CA3035252C/en active Active
- 2017-08-30 JP JP2019531596A patent/JP6864747B2/en active Active
- 2017-08-30 CU CU2019000015A patent/CU20190015A7/en unknown
- 2017-08-30 EP EP17847485.4A patent/EP3506886B1/en active Active
- 2017-08-30 UA UAA201903034A patent/UA122733C2/en unknown
- 2017-08-30 SG SG10202100697PA patent/SG10202100697PA/en unknown
- 2017-08-30 GE GEAP201715038A patent/GEP20217252B/en unknown
- 2017-08-30 US US15/691,266 patent/US11628217B2/en active Active
- 2017-08-30 AU AU2017321605A patent/AU2017321605B2/en active Active
- 2017-08-30 PE PE2019000408A patent/PE20190469A1/en unknown
- 2017-08-30 CN CN202210971401.6A patent/CN116327695A/en active Pending
- 2017-08-30 MY MYPI2019000424A patent/MY189411A/en unknown
- 2017-08-30 IL IL265071A patent/IL265071B2/en unknown
- 2017-08-30 EA EA201990598A patent/EA201990598A1/en unknown
- 2017-08-30 MX MX2019002338A patent/MX2019002338A/en unknown
- 2017-08-30 KR KR1020217035424A patent/KR102444154B1/en active IP Right Grant
- 2017-08-30 BR BR112019003479-0A patent/BR112019003479A2/en active Search and Examination
- 2017-08-30 CN CN202210971376.1A patent/CN116327917A/en active Pending
- 2017-08-30 SG SG11201901444PA patent/SG11201901444PA/en unknown
- 2017-08-31 AR ARP170102432A patent/AR109494A1/en unknown
- 2017-08-31 UY UY0001037391A patent/UY37391A/en unknown
-
2019
- 2019-02-20 PH PH12019500365A patent/PH12019500365A1/en unknown
- 2019-02-26 CL CL2019000508A patent/CL2019000508A1/en unknown
- 2019-02-26 MX MX2023014120A patent/MX2023014120A/en unknown
- 2019-03-11 CO CONC2019/0002239A patent/CO2019002239A2/en unknown
- 2019-03-27 ZA ZA2019/01891A patent/ZA201901891B/en unknown
- 2019-03-27 EC ECSENADI201921312A patent/ECSP19021312A/en unknown
-
2020
- 2020-11-24 AU AU2020277135A patent/AU2020277135B2/en active Active
-
2021
- 2021-04-02 JP JP2021063245A patent/JP7197623B2/en active Active
-
2023
- 2023-02-28 US US18/176,155 patent/US20230226178A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
SG11201900606VA (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908540PA (en) | Stable antibody formulation | |
SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201909547TA (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201909918XA (en) | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201811251RA (en) | Multi-chamber deposition equipment for solid free form fabrication | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201902531QA (en) | Liquid pharmaceutical composition | |
SG11201803676PA (en) | Site specific her2 antibody drug conjugates | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |